

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Improved perceptions of the bladder condition	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	175/349	246/474	0.96 (0.84; 1.10)	-0.02 (-0.09; 0.05)		
Zero episodes of dry mouth	Armstrong, 2005 ²³¹	10mg/day	4mg daily	281/391	313/399	0.92 (0.85; 0.99)	-0.07 (-0.13; -0.01)	-15 (-176; -8)	-66 (-126; -6)
Adverse events	Armstrong, 2007 ²³²	10mg qd	4mg qd	404/576	254/399	1.10 (1.01; 1.21)	0.07 (0.01; 0.13)	15 (8; 218)	65 (5; 125)
Adverse events	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	262/349	351/474	1.01 (0.94; 1.10)	0.01 (-0.05; 0.07)		
Serious adverse events	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	14/349	19/474	1.00 (0.51; 1.97)	0.00 (-0.03; 0.03)		
Serious adverse events	Appell, 1997 ²²⁹	5mg/day	2mg/day	14/349	19/474	1.00 (0.51; 1.97)	0.00 (-0.027; 0.027)		
Mild adverse events related to treatment	Armstrong, 2007 ²³²	10mg qd	2mg bid	217/576	81/193	0.90 (0.74; 1.09)	-0.043 (-0.12; 0.04)		
Moderate adverse events related to treatment	Armstrong, 2007 ²³²	10mg qd	4mg qd	103/576	40/399	1.78 (1.27; 2.51)	0.08 (0.04; 0.12)	13 (8; 28)	79 (36; 122)
Moderate adverse events related to treatment	Armstrong, 2007 ²³²	10mg qd	2mg bid	103/576	35/193	0.99 (0.70; 1.40)	-0.00 (-0.07; 0.06)		
Severe adverse events related to treatment	Armstrong, 2007 ²³²	10mg qd	2mg bid	25/576	5/193	1.68 (0.65; 4.32)	0.02 (-0.01; 0.05)		
Severe adverse events related to treatment	Armstrong, 2007 ²³²	10mg qd	4mg qd	25/576	6/399	2.89 (1.20; 6.97)	0.03 (0.01; 0.05)	35 (20; 127)	28 (8; 49)
Withdrawal	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	94/349	63/474	2.03 (1.52; 2.70)	0.14 (0.08; 0.19)		
Withdrawal	Armstrong, 2005 ²³¹	10mg/day	4mg daily	52/391	42/399	1.26 (0.86; 1.85)	0.03 (-0.02; 0.07)		
Patients with at least one adverse event leading to study drug discontinuation	Armstrong, 2007 ²³²	10mg qd	4mg qd	35/576	19/399	1.28 (0.74; 2.20)	0.01 (-0.02; 0.04)		

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs) (continued)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Patients with at least one adverse event leading to study drug discontinuation	Armstrong, 2007 ²³²	10mg qd	2mg bid	35/576	15/193	0.78 (0.44; 1.40)	-0.02 (-0.06; 0.03)		
Withdrawal due to adverse events	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	70/349	38/474	2.50 (1.73; 3.62)	0.12 (0.07; 0.17)	8 (6; 14)	120 (72; 169)
Withdrawal due to adverse events	Armstrong, 2005 ²³¹	10mg/day	4mg daily	52/391	42/399	1.26 (0.86; 1.85)	0.03 (-0.02; 0.07)		
Withdrawal due to adverse events	Armstrong, 2005 ²³¹	10mg/day	4mg daily	20/391	19/399	1.07 (0.58; 1.98)	0.00 (-0.03; 0.03)		
Withdrawal due to dry mouth	Armstrong, 2005 ²³¹	10mg/day	4mg daily	110/391	86/399	1.31 (1.02; 1.67)	0.07 (0.01; 0.13)	15 (8; 176)	66 (6; 126)
Dose reduction in case of intolerance	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	112/349	43/474	3.54 (2.56; 4.89)	0.23 (0.18; 0.29)	4 (4; 6)	230 (175; 286)
Asthenia	Armstrong, 2007 ²³²	10mg qd	4mg qd	17/576	0/399	24.26 (1.46; 402.30)	0.03 (0.02; 0.04)	34 (23; 66)	30 (15; 44)
Autonomic nervous system disorder	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	283/349	204/474	1.88 (1.68; 2.11)	0.38 (0.32; 0.44)	3 (2; 3)	381 (320; 441)
Autonomic nervous system disorder	Appell, 1997 ²²⁹	5mg/day	2mg/day	283/349	204/474	1.88 (1.68; 2.11)	0.38 (0.32; 0.44)	3 (2; 3)	381 (320; 441)
Autonomic nervous system disorder	Appell, 1997 ²²⁹	5mg/day	1mg/day	283/349	35/121	2.80 (2.11; 3.72)	0.52 (0.43; 0.61)	2 (2; 2)	52 (431; 612)
Discontinuation due to adverse effect on a body as a whole	Armstrong, 2007 ²³²	10mg qd	4mg qd	155/576	85/399	1.26 (1.00; 1.59)	0.06 (0.01; 0.11)	18 (9; 507)	5 6(2; 110)
Gastrointestinal disorders	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	140/349	123/474	1.55 (1.27; 1.89)	0.14 (0.08; 0.21)	7 (5; 13)	142 (77; 206)
Dry mouth	Armstrong, 2007 ²³²	10mg qd	4mg qd	169/576	92/399	1.27 (1.02; 1.58)	0.06 (0.01; 0.12)	16 (8; 138)	63 (7; 118)
Dry mouth	Armstrong, 2007 ²³²	10mg qd	4mg qd	169/576	89/399	1.32 (1.05; 1.64)	0.07 (0.02; 0.13)	14 (8; 66)	70 (15; 126)
Dry mouth	Appell, 1997 ²²⁹	5mg/day	2mg/day	272/349	190/474	1.94 (1.72; 2.20)	0.379 (0.32; 0.44)	3 (2; 3)	379 (317; 440)
Dry mouth	Appell, 1997 ²²⁹	5mg/day	1mg/day	272/349	29/121	3.25 (2.36; 4.49)	0.54 (0.45; 0.63)	2 (2; 2)	540 (452; 627)

Appendix Table F76. Comparative effectiveness of oxybutynin vs. tolterodine (secondary data analyses using individual patient data from RCTs) (continued)

Outcomes	Reference	Oxybutynin dose	Tolterodine dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable effects/1000 treated (95% CI)
Dry mouth-onset at 1 month	Armstrong, 2005 ²³¹	10mg/day	4mg daily	101/391	74/399	1.39 (1.07; 1.82)	0.07 (0.02; 0.13)	14 (8; 66)	73 (15; 131)
Dyspepsia	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	38/349	28/474	1.84 (1.15; 2.94)	0.05 (0.01; 0.09)	20 (11; 92)	50 (11; 89)
Gastrointestinal disorders	Appell, 1997 ²²⁹	5mg/day	1mg/day	140/349	27/121	1.80 (1.26; 2.57)	0.178 (0.09; 0.27)	6 (4; 11)	178 (88; 268)
Moderate or severe dry mouth	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	209/349	81/474	3.50 (2.82; 4.35)	0.428 (0.37; 0.49)	2 (2; 3)	428 (366; 490)
Nausea	Armstrong, 2007 ²³²	10mg qd	4mg qd	14/576	0/399	20.10 (1.20; 336.04)	0.02 (0.01; 0.04)	41 (27; 90)	24 (11; 38)
Pain	Armstrong, 2007 ²³²	10mg qd	4mg qd	22/576	0/399	31.20 (1.90; 512.77)	0.04 (0.02; 0.05)	26 (18; 45)	38 (22; 54)
Palpitations	Appell, 1997 ²²⁹	5mg three times daily	2mg twice daily	8/349	2/474	5.43 (1.16; 25.43)	0.02 (0.00; 0.04)	53 (28; 512)	19 (2; 35)
Rhinitis	Armstrong, 2007 ²³²	10mg qd	4mg qd	10/576	0/399	14.56 (0.86; 247.72)	0.02 (0.01; 0.03)	58 (35; 169)	17 (6; 29)
Severe dry mouth	Appell, 1997 ²²⁹	5mg/day	2mg/day	209/349	81/474	3.50 (2.82; 4.35)	0.43 (0.37; 0.49)	2 (2; 3)	428 (366; 490)
Severe dry mouth	Appell, 1997 ²²⁹	5mg/day	1mg/day	209/349	5/121	14.49 (6.12; 34.33)	0.56 (0.50; 0.62)	2 (2; 2)	558 (495; 620)
Symptoms associated with urinary emptying	Armstrong, 2007 ²³²	10mg qd	4mg qd	55/576	22/399	1.73 (1.07; 2.79)	0.04 (0.01; 0.07)	25 (14; 133)	40 (8; 73)
Urinary tract infection	Armstrong, 2007 ²³²	10mg qd	4mg qd	30/576	0/399	42.29 (2.59; 689.54)	0.05 (0.03; 0.07)	19 (14; 30)	52 (34; 71)
Urogenital system adverse effects	Armstrong, 2007 ²³²	10mg qd	4mg qd	92/576	38/399	1.68 (1.18; 2.39)	0.06 (0.02; 0.11)	16 (9; 44)	64 (23; 106)